このエピソードについて

英語
アメリカ合衆国

文字起こし 🔗

過去のエピソードを検索

PharmaSource Podcastの以前のエピソードを検索します。

このポッドキャストの他のエピソード

“AI is marketed as such an approachable, ubiquitous thing that everybody thinks they can vibe code it. Unfortunately, a lot of companies are starting to think that way,” says Kat Kozyrytska. Kat Kozyrytska is a portfolio strategy and technology leader in life science technologies who has operated …
Sponsored by Blue Jet Healthcare, this panel at CDMO Live Europe 2026 brought together Bernhard Boehm, Head of External Manufacturing Animal Health, Boehringer Ingelheim; Philip Coetzee, Director CMO Management, Daiichi Sankyo Europe; Fanny Eberhardt, Director Global Procurement, UCB; and Shiven Ar…
“How good is your AI model? That’s the wrong question. The right question is: what does your AI model actually help your company do?” Seungik Cho, founder of Sapiens Health, has spent the past year pulling apart the assumption in biomanufacturing that a better-predicting AI model means a better dig…
“Traditional staff augmentation says, ‘Here are the people you asked for.’ An outcome-led model says, ‘Here is the service or capability you asked for, and we are accountable and responsible for making it work.’” — Aisling Flanagan Aisling Flanagan, Global SVP of Professional and Managed Services a…
At CDMO Live Europe 2026, Dr. Olivier Aebischer, Deputy CEO at Interlabor Belp AG, demonstrated how a structured, dual-path analytical approach can identify manufacturing root causes in days, using two real contamination case studies from the lab’s operations.
免責: このページに埋め込まれているポッドキャストとアートワークは Life Science Networks からのものであり、その所有者の所有物であり、Listen Notes, Inc. と提携または承認されていません。